Elevance Health Rises 2.1% on Earnings Beat and Upgraded 2026 Guidance

Key Facts

1Elevance Health stock closed up 2.1% at $347.84 on the NYSE on September 22, 2026.

2The company reported quarterly revenue of $49.83 billion and earnings per share of $7.45, exceeding consensus estimates.

3Elevance Health raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75.

Reflecting strong operational momentum within the healthcare sector, Elevance Health reported financial results that surpassed market expectations. The company's stock closed up 2.1% at $347.84 on the NYSE on September 22, 2026. This upward movement followed the reporting of quarterly revenue of $49.83 billion and earnings per share of $7.45, both of which exceeded consensus analyst estimates.

Per market data, the results showed a revenue increase of 0.8% compared to the same quarter a year earlier, while the benefit expense ratio for the first quarter stood at 86.8%. Consequently, the company raised its full-year 2026 adjusted diluted EPS guidance by $1.25 to at least $26.75, signaling confidence in its ability to manage medical costs and drive profitability growth.

At the close of September 22, 2026, ELV was priced at $402.43 according to database records, having reached a day high of $412.75. Moving forward, investors should monitor upcoming US retail sales and building permits data for broader insights into consumer health, which remains a secondary driver for the insurance and healthcare services industry.